Italian authorities on Monday appointed a special commissioner to help Danish drugmaker Novo Nordisk speedily deliver its ...

Years before semaglutide became a blockbuster drug for Novo Nordisk, the Danish pharma giant had the chance to maintain its patent in Canada but didn’t pay a small fee to do so, according to a ...

Collaboration combines Novo Nordisk’ s scientific leadership in obesity and cardiometabolic diseases with Septerna’ s expertise in G protein-coupled receptor drug discovery Goal is to develop ...

Wegovy maker Novo Nordisk has hired the start-up Deep Apple Therapeutics to develop small molecules as its next weight-loss play.

Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. The Danish drugmaker on Friday abruptly announced that longtime CEO Lars Fruergaard ...

Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Novo Nordisk has planted another seed to fuel the blossoming of its obesity business, inking an $812 million deal with Deep Apple Therapeutics to access small molecules against a non-incretin GPCR ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the competitive weight-loss drug market.

Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with the company’s board of directors ...

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight loss treatments.

Novo Nordisk NOVO.B -1.53% shares rallied Wednesday as investors breathed a sigh of relief after first-quarter earnings beat expectations and the company’s guidance cut mirrored expectations.